QLT initiates CORE study, evaluating drug delivery system for POAG and OH patients

Article

QLT Inc. has begun patient recruitment into its "CORE" study, a Phase II randomized, masked, parallel-group study of safety and preliminary efficacy of a punctal plug drug delivery system in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).

QLT Inc. has begun patient recruitment into its "CORE" study, a Phase II randomized, masked, parallel-group study of safety and preliminary efficacy of a punctal plug drug delivery system in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).

QLT's system is non-invasive and consists of three different concentrations of latanoprost, a prostaglandin analogue. It is being developed with the goal of being capable of delivering a variety of drugs to the eye over time through sustained release to the tear film for periods of approximately 90 days, with the aim of inducing a therapeutic drop in IOP.

The study objectives are to investigate the preliminary efficacy and safety of the punctal plug drug delivery system, and to determine an appropriate concentration(s) of drug to advance into late-stage development. Enrolled subjects will be randomized in an equal ratio to receive one of three concentrations (low, medium, high) and will be followed for 16 weeks.

Preliminary efficacy will be evaluated by the proportion of 60 subjects who have not lost efficacy, defined as an IOP increase to within 2 mmHg below baseline IOP while wearing a punctal plug with drug that has been continuously in place since Day 0, and with IOP variables including Goldmann IOP measurements, IOP change from baseline, and percentage IOP change from baseline.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.